AR and prostate carcinoma: Fusions of TMPRSS2 with the ETS family of genes, such as ERG and ET1, the amplification of the oncogene MYC, deletion or mutations of tumor suppressors TP53 and PTEN, and amplification of the androgen receptor (AR) are other key genetic alterations found in different stages in prostate cancer [80,82,83,84,85,86].